0VQA Stock Overview
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Viking Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$65.14 |
| 52 Week High | US$99.30 |
| 52 Week Low | US$8.88 |
| Beta | 1.1 |
| 1 Month Change | -6.44% |
| 3 Month Change | 192.25% |
| 1 Year Change | 210.05% |
| 3 Year Change | 973.23% |
| 5 Year Change | n/a |
| Change since IPO | 341.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0VQA | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -6.8% | -2.3% | -0.7% |
| 1Y | 210.1% | -29.4% | -1.8% |
Return vs Industry: 0VQA exceeded the UK Biotechs industry which returned -29.4% over the past year.
Return vs Market: 0VQA exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0VQA volatility | |
|---|---|
| 0VQA Average Weekly Movement | 36.0% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0VQA's share price has been volatile over the past 3 months.
Volatility Over Time: 0VQA's weekly volatility has increased from 21% to 36% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 27 | Brian Lian | www.vikingtherapeutics.com |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
Viking Therapeutics, Inc. Fundamentals Summary
| 0VQA fundamental statistics | |
|---|---|
| Market cap | US$7.13b |
| Earnings (TTM) | -US$85.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-83.0x
P/E RatioIs 0VQA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0VQA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$85.90m |
| Earnings | -US$85.89m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 24, 2024
| Earnings per share (EPS) | -0.78 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0VQA perform over the long term?
See historical performance and comparison